vs
STONERIDGE INC（SRI）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
STONERIDGE INC的季度营收约是再鼎医药的1.6倍（$205.2M vs $127.1M），再鼎医药同比增速更快（17.1% vs -6.0%），STONERIDGE INC自由现金流更多（$2.6M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs -7.4%）
Stoneridge Inc是全球领先的电气电子元件、集成系统及传感器解决方案设计制造商，服务汽车、商用车、非道路设备与航空航天领域，产品可提升车辆安全性、运行效率、互联性与环保表现，业务覆盖全球核心市场。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
SRI vs ZLAB — 直观对比
营收规模更大
SRI
是对方的1.6倍
$127.1M
营收增速更快
ZLAB
高出23.1%
-6.0%
自由现金流更多
SRI
多$29.3M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
-7.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $205.2M | $127.1M |
| 净利润 | — | — |
| 毛利率 | 16.2% | 51.0% |
| 营业利润率 | -14.4% | -54.6% |
| 净利率 | — | — |
| 营收同比 | -6.0% | 17.1% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $-2.76 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收SRIZLAB
| Q4 25 | $205.2M | $127.1M | ||
| Q3 25 | $210.3M | $115.4M | ||
| Q2 25 | $228.0M | $109.1M | ||
| Q1 25 | $217.9M | $105.7M | ||
| Q4 24 | $218.2M | $108.5M | ||
| Q3 24 | $213.8M | $101.8M | ||
| Q2 24 | $237.1M | $100.1M | ||
| Q1 24 | $239.2M | $87.1M |
净利润SRIZLAB
| Q4 25 | — | — | ||
| Q3 25 | $-9.4M | $-36.0M | ||
| Q2 25 | $-9.4M | $-40.7M | ||
| Q1 25 | $-7.2M | $-48.4M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-7.1M | $-41.7M | ||
| Q2 24 | $2.8M | $-80.3M | ||
| Q1 24 | $-6.1M | $-53.5M |
毛利率SRIZLAB
| Q4 25 | 16.2% | 51.0% | ||
| Q3 25 | 20.3% | 59.5% | ||
| Q2 25 | 21.5% | 60.6% | ||
| Q1 25 | 21.2% | 63.6% | ||
| Q4 24 | 19.5% | 61.5% | ||
| Q3 24 | 20.8% | 64.1% | ||
| Q2 24 | 22.7% | 64.9% | ||
| Q1 24 | 20.2% | 61.4% |
营业利润率SRIZLAB
| Q4 25 | -14.4% | -54.6% | ||
| Q3 25 | -1.6% | -42.3% | ||
| Q2 25 | -1.1% | -50.3% | ||
| Q1 25 | -1.5% | -53.3% | ||
| Q4 24 | -2.0% | -62.6% | ||
| Q3 24 | 0.1% | -66.6% | ||
| Q2 24 | 1.4% | -76.0% | ||
| Q1 24 | 0.1% | -80.7% |
净利率SRIZLAB
| Q4 25 | — | — | ||
| Q3 25 | -4.5% | -31.2% | ||
| Q2 25 | -4.1% | -37.3% | ||
| Q1 25 | -3.3% | -45.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | -3.3% | -40.9% | ||
| Q2 24 | 1.2% | -80.2% | ||
| Q1 24 | -2.6% | -61.4% |
每股收益（稀释后）SRIZLAB
| Q4 25 | $-2.76 | $-0.05 | ||
| Q3 25 | $-0.34 | $-0.03 | ||
| Q2 25 | $-0.34 | $-0.04 | ||
| Q1 25 | $-0.26 | $-0.04 | ||
| Q4 24 | $-0.22 | $-0.09 | ||
| Q3 24 | $-0.26 | $-0.04 | ||
| Q2 24 | $0.10 | $-0.08 | ||
| Q1 24 | $-0.22 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $66.3M | $689.6M |
| 总债务越低越好 | $180.9M | — |
| 股东权益账面价值 | $179.8M | $715.5M |
| 总资产 | $551.2M | $1.2B |
| 负债/权益比越低杠杆越低 | 1.01× | — |
8季度趋势，按日历期对齐
现金及短期投资SRIZLAB
| Q4 25 | $66.3M | $689.6M | ||
| Q3 25 | $54.0M | $717.2M | ||
| Q2 25 | $49.8M | $732.2M | ||
| Q1 25 | $79.1M | $757.3M | ||
| Q4 24 | $71.8M | $779.7M | ||
| Q3 24 | $54.1M | $616.1M | ||
| Q2 24 | $42.1M | $630.0M | ||
| Q1 24 | $48.4M | $650.8M |
总债务SRIZLAB
| Q4 25 | $180.9M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $201.6M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益SRIZLAB
| Q4 25 | $179.8M | $715.5M | ||
| Q3 25 | $251.2M | $759.9M | ||
| Q2 25 | $260.5M | $791.7M | ||
| Q1 25 | $253.1M | $810.8M | ||
| Q4 24 | $245.3M | $840.9M | ||
| Q3 24 | $271.4M | $667.7M | ||
| Q2 24 | $270.5M | $704.2M | ||
| Q1 24 | $277.3M | $762.2M |
总资产SRIZLAB
| Q4 25 | $551.2M | $1.2B | ||
| Q3 25 | $632.1M | $1.2B | ||
| Q2 25 | $639.4M | $1.2B | ||
| Q1 25 | $657.4M | $1.2B | ||
| Q4 24 | $621.6M | $1.2B | ||
| Q3 24 | $662.5M | $985.3M | ||
| Q2 24 | $666.7M | $987.4M | ||
| Q1 24 | $675.4M | $988.4M |
负债/权益比SRIZLAB
| Q4 25 | 1.01× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $8.8M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $2.6M | $-26.7M |
| 自由现金流率自由现金流/营收 | 1.3% | -21.0% |
| 资本支出强度资本支出/营收 | 3.0% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $12.2M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流SRIZLAB
| Q4 25 | $8.8M | $-26.0M | ||
| Q3 25 | $3.6M | $-32.0M | ||
| Q2 25 | $10.7M | $-31.0M | ||
| Q1 25 | $10.9M | $-61.7M | ||
| Q4 24 | $19.2M | $-55.8M | ||
| Q3 24 | $10.8M | $-26.8M | ||
| Q2 24 | $8.7M | $-42.2M | ||
| Q1 24 | $9.1M | $-90.1M |
自由现金流SRIZLAB
| Q4 25 | $2.6M | $-26.7M | ||
| Q3 25 | $-2.7M | $-35.0M | ||
| Q2 25 | $7.4M | $-33.9M | ||
| Q1 25 | $4.8M | $-63.2M | ||
| Q4 24 | $14.0M | $-58.4M | ||
| Q3 24 | $4.6M | $-28.2M | ||
| Q2 24 | $1.5M | $-42.9M | ||
| Q1 24 | $3.3M | $-91.1M |
自由现金流率SRIZLAB
| Q4 25 | 1.3% | -21.0% | ||
| Q3 25 | -1.3% | -30.4% | ||
| Q2 25 | 3.3% | -31.1% | ||
| Q1 25 | 2.2% | -59.9% | ||
| Q4 24 | 6.4% | -53.8% | ||
| Q3 24 | 2.2% | -27.7% | ||
| Q2 24 | 0.6% | -42.9% | ||
| Q1 24 | 1.4% | -104.5% |
资本支出强度SRIZLAB
| Q4 25 | 3.0% | 0.5% | ||
| Q3 25 | 3.0% | 2.6% | ||
| Q2 25 | 1.4% | 2.6% | ||
| Q1 25 | 2.8% | 1.5% | ||
| Q4 24 | 2.4% | 2.4% | ||
| Q3 24 | 2.9% | 1.3% | ||
| Q2 24 | 3.0% | 0.7% | ||
| Q1 24 | 2.4% | 1.1% |
现金转化率SRIZLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 3.11× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
SRI
| Control Devices | $51.7M | 25% |
| Electronics | $38.0M | 19% |
| EE | $34.2M | 17% |
| SE | $28.6M | 14% |
| NL | $24.5M | 12% |
| Stoneridge Brazil | $14.1M | 7% |
| Asia Pacific | $13.1M | 6% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
